TGF-β signaling via TAK1 pathway: role in kidney fibrosis. Review uri icon

Overview

abstract

  • In progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney failure. Transforming growth factor-β1 (TGF-β1) is a pleiotropic cytokine that has been established as a central mediator of kidney fibrosis. Emerging evidence shows a complex scheme of signaling networks that enable multifunctionality of TGF-β1 actions. Specific targeting of the TGF-β signaling pathway is seemingly critical and an attractive molecular therapeutic strategy. TGF-β1 signals through the interaction of type I and type II receptors to activate distinct intracellular pathways involving the Smad and the non-Smad. The Smad signaling axis is known as the canonical pathway induced by TGF-β1. Importantly, recent investigations have shown that TGF-β1 also induces various non-Smad signaling pathways. In this review, we focus on current insights into the mechanism and function of the Smad-independent signaling pathway via TGF-β-activated kinase 1 and its role in mediating the profibrotic effects of TGF-β1.

publication date

  • May 1, 2012

Research

keywords

  • Kidney
  • MAP Kinase Kinase Kinases
  • Renal Insufficiency, Chronic
  • Transforming Growth Factor beta1

Identity

PubMed Central ID

  • PMC3407377

Scopus Document Identifier

  • 84864120935

Digital Object Identifier (DOI)

  • 10.1016/j.semnephrol.2012.04.003

PubMed ID

  • 22835455

Additional Document Info

volume

  • 32

issue

  • 3